Obestatin

Obestatin is a 23-amino acid peptide encoded by the same preproghrelin gene that produces ghrelin, discovered in 2005. Initially described as a ghrelin antagonist that suppressed food intake and gastric motility, subsequent research yielded conflicting results, making obestatin one of the most contested peptides in metabolic endocrinology. Current evidence suggests it functions as an independent multi-functional hormone rather than a simple ghrelin antagonist.

Obestatin was originally reported to bind GPR39 (an orphan GPCR) and oppose ghrelin's orexigenic actions. However, multiple independent groups failed to confirm GPR39 binding or a consistent anorexigenic effect. More recent studies indicate obestatin signals through pathways including GLP-1 receptor cross-talk and phospholipase C activation. It may regulate glucose metabolism, pancreatic beta-cell survival, and smooth muscle contractility independently of ghrelin. The definitive receptor and downstream cascade remain contested in the literature.

The 2005 Science paper reporting obestatin's discovery generated immediate interest but proved difficult to replicate. Multiple groups reported absence of satiety effects or GPR39 binding. Current research pivots toward obestatin's potential roles in cell survival (particularly pancreatic islets and cardiomyocytes), gastric adaptation, and reproductive function. Plasma obestatin levels are altered in obesity, polycystic ovary syndrome, and Prader-Willi syndrome. No therapeutic applications have advanced to clinical trials.